Teplizumab, a new drug, could delay the need for insulin for patients with type 1 diabetes by up to 3 years.
Călin Nicolescu
Health
Foto Pixabay
Always see our news on Google
Teplizumab, a drug already approved in the US, is being tested in the UK to slow the progression of type 1 diabetes by training the immune system to protect pancreatic cells. Hannah Robinson, the first British adult to receive the treatment, hopes it will delay the need for insulin. Experts believe the treatment represents a major change in diabetes management, with the potential to alter the immune process and help high-risk people avoid insulin therapy.
Sources
Un medicament "revoluţionar" ar putea încetini evoluţia diabetului de tip 1. Poate întârzia nevoia de insulină cu 3 ani
Devon mother treated with game-changing diabetes drug
Mother of two becomes the first UK patient to receive ‘groundbreaking’ new diabetes drug
Un medicament „revoluționar”, o nouă speranță pentru diabetul de tip 1. Ce așteptări au medicii
Latest News
21:13
The ANI law was rejected in the Senate. Romania risks losing 770 million euros from the PNRR.
21:10
EPPO requests for the second time the lifting of the immunity of a Polish deputy in an investigation regarding European funds
21:03
Adidas stated that the appearance of the pink football boot on the fields of the 2026 World Cup was a coincidence, not a marketing strategy.
20:49
Member of the European Parliament Diana Iovanovici-Șoșoacă announced that she is feeling well after the road accident in which she was involved, thanking the doctors and supporters for their support.
20:35
The Senate has adopted the Territorial Planning, Urbanism and Constructions Code, which will digitalize the approval of constructions and reduce bureaucracy.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
